Challenges in the development of orally bioavailable thrombin active site inhibitors

S. D. Kimball

Research output: Contribution to journalReview articlepeer-review

64 Scopus citations


Activated thrombin plays a central role thrombosis and in hemostasis, both by controlling the coagulation process, and by activating receptors on platelets and various cell types. A safe and effective inhibitor of thrombin active site could be a useful tool in the treatment of venous thrombosis, atrial fibrillation, restenosis, arterial thrombosis, and in the prevention of myocardial infarction. Because of this, the modulation of thrombin by direct, small molecule inhibitors is a widely sought goal in the pharmaceutical industry. However, this search has thus far proved elusive. Criteria for a pharmaceutically acceptable thrombin inhibitor include high and reproducible bioavailability, selectivity, and a long duration of action. The profile of currently researched thrombin active site inhibitors is discussed in relation to these goals.

Original languageEnglish (US)
Pages (from-to)511-519
Number of pages9
JournalBlood Coagulation and Fibrinolysis
Issue number6
StatePublished - 1995
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology


  • Active site
  • Efficacy
  • Enzyme selectivity
  • Oral bioavailability
  • Pharmacodynamics
  • Pharmacokinetics
  • Rebound
  • Thrombin inhibitor


Dive into the research topics of 'Challenges in the development of orally bioavailable thrombin active site inhibitors'. Together they form a unique fingerprint.

Cite this